Dr. Jessie Yanxiang Guo received her Degree of Medicine from the Beijing Medical University in Beijing, China. She then joined the Institute of Basic Science of Medicine, where she received her Master of Medicine degree, and began her research career in the field of cancer immunology. She received her Ph.D. degree through the Department of Molecular Cancer Biology and Pharmacology at Duke University under the supervision of Dr. Sally Kornbluth, where she obtained extensive training in biochemistry, cell cycle, cell death, and cancer biology. As a Postdoctoral fellow, she joined the laboratory of Dr. Eileen White at Rutgers Cancer Institute of New Jersey and became immersed in the fields of autophagy and cancer metabolism, utilizing genetically engineered mouse models for human cancers and state-of-the-art metabolomics.
Dr. Guo is currently a Tenured Associate Professor in the Division of Medical Oncology, Department of Medicine at the Robert Wood Johnson Medical School, and is a Resident Member at Rutgers Cancer Institute of New Jersey. Over the past few years, she has made significant contributions to understanding the role and underlying mechanisms of autophagy in supporting KRAS-driven lung cancer and the potential use of autophagy inhibitors in cancer therapy. Moreover, Dr. Guo's research interests extend beyond autophagy, as she is interested in identifying other novel metabolic vulnerabilities that could be exploited for the treatment of KRAS-driven NSCLC.
Dr. Guo’s research is currently supported by the National Cancer Institute (NCI) (R01CA237347, R21CA263136), the American Cancer Society (ACS), the American Lung Association, Ludwig Institute for Cancer Research at Ludwig Princeton Branch, and the New Jersey State Commission on Cancer Research (NJCCR). In addition, she was formerly supported by the NCI Transition Career Development Award (K22CA190521), GO2 Foundation for Lung Cancer's Young Innovators Team Awards, Lung Cancer Research Foundation Award, and New Jersey Health Foundation Award.